This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...
Serial circulating tumor DNA analysis can demonstrate rapid clonal dynamics that evolve during response and resistance to both standard chemotherapy and targeted therapy of BRAF-mutant colon cancer ...
I’d like to discuss here the evolving therapeutic landscape in NF1. For the past several years, the NF scientific community, including the UAB NF Research Program, has put major emphasis on conducting ...
Most patients with vascular anomalies treated with the mitogen-activated protein kinase (MEK) inhibitors, trametinib and selumetinib, experienced cutaneous adverse events (CAEs). “Multidisciplinary ...
SEOUL, South Korea -- The combination of avutometinib and defactinib achieved "exceptionally" high response rates in heavily pretreated patients with recurrent low-grade serous ovarian cancer (LGSOC), ...
Cutaneous squamous cell carcinoma (cSCC) is a common form of skin cancer often caused by chronic exposure to ultraviolet (UV) radiation. Addressing the need for effective chemopreventive strategies, a ...
A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer. A phase 3 trial analyzing the treatment combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results